This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, Guglielmelli P, Pungolino E, Caramella M, Maffioli M, Pascutto C, Lazzarino M, Cazzola M, Tefferi A (2010) A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 115:1703–1708. https://doi.org/10.1182/blood-2009-09-245837
Gangat N, Caramazza D, Vaidya R et al (2010) DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. JCO 29:392–397. https://doi.org/10.1200/JCO.2010.32.2446
Kröger NM, Deeg JH, Olavarria E, Niederwieser D, Bacigalupo A, Barbui T, Rambaldi A, Mesa R, Tefferi A, Griesshammer M, Gupta V, Harrison C, Alchalby H, Vannucchi AM, Cervantes F, Robin M, Ditschkowski M, Fauble V, McLornan D, Ballen K, Popat UR, Passamonti F, Rondelli D, Barosi G (2015) Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. Leukemia 29:2126–2133. https://doi.org/10.1038/leu.2015.233
Bacigalupo A, Soraru M, Dominietto A, Pozzi S, Geroldi S, van Lint M, Ibatici A, Raiola AM, Frassoni F, de Stefano F, Verdiani S, Casarino L, Barosi G (2010) Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type. Bone Marrow Transplant 45:458–463. https://doi.org/10.1038/bmt.2009.188
Kroger N, Holler E, Kobbe G et al (2009) Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 114:5264–5270. https://doi.org/10.1182/blood-2009-07-234880
Robin M, Zine M, Chevret S, Meignin V, Munoz-Bongrand N, Moatti H, Xhaard A, Sicre de Fontbrune F, Peffault de Latour R, Sarfati E, Socié G (2017) The impact of splenectomy in myelofibrosis patients before allogeneic hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation 23:958–964. https://doi.org/10.1016/j.bbmt.2017.03.002
Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, Pham HP, Schneiderman J, Witt V, Wu Y, Zantek ND, Dunbar NM, Schwartz GEJ (2019) Guidelines on the use of therapeutic apheresis in clinical practice – evidence-based approach from the writing Committee of the American Society for Apheresis: the eighth special issue. J Clin Apher 34:171–354. https://doi.org/10.1002/jca.21705
Orlin JB, Berkman EM (1980) Improvement of platelet function following plateletpheresis in patients with myeloproliferative diseases. Transfusion 20:540–545. https://doi.org/10.1046/j.1537-2995.1980.20581034507.x
Conflict of interest
All authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from the patient included in the study.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Debureaux, P., Brignier, A., Soret-Dulphy, J. et al. Thrombocytapheresis and sequential chemotherapy for extreme symptomatic thrombocytosis secondary to myelofibrosis: a case report. Ann Hematol (2020). https://doi.org/10.1007/s00277-020-03948-0